Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Receivables Refunds (2021 - 2025)

Indivior Pharmaceuticals has reported Receivables Refunds over the past 4 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Receivables Refunds at $2.0 million for Q4 2025, down 93.94% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 93.94% YoY), and the annual figure for FY2025 was $2.0 million, down 93.94%.
  • Receivables Refunds for Q4 2025 was $2.0 million at Indivior Pharmaceuticals, down from $13.0 million in the prior quarter.
  • Over the last five years, Receivables Refunds for INDV hit a ceiling of $33.0 million in Q4 2024 and a floor of $2.0 million in Q4 2025.
  • Median Receivables Refunds over the past 4 years was $13.0 million (2021), compared with a mean of $14.0 million.
  • Biggest five-year swings in Receivables Refunds: crashed 61.54% in 2022 and later tumbled 93.94% in 2025.
  • Indivior Pharmaceuticals' Receivables Refunds stood at $13.0 million in 2021, then crashed by 61.54% to $5.0 million in 2022, then skyrocketed by 560.0% to $33.0 million in 2024, then tumbled by 93.94% to $2.0 million in 2025.
  • The last three reported values for Receivables Refunds were $2.0 million (Q4 2025), $13.0 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.